EGFR and non-small cell lung carcinoma: However, a study with 9649 Chinese primary NSCLC patients reported no significant differences in PD-L1 expression, TMB level or CD8+ T-cell infiltration between these two EGFR subtypes irrespective of treatment exposure (29).